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Large-scale proteomic analysis of human brain
identiﬁes proteins associated with cognitive
trajectory in advanced age
Aliza P. Wingo1,2, Eric B. Dammer 3, Michael S. Breen4,5,6, Benjamin A. Logsdon 7, Duc M. Duong3,
Juan C. Troncosco8, Madhav Thambisetty9, Thomas G. Beach10, Geidy E. Serrano10, Eric M. Reiman11,
Richard J. Caselli12, James J. Lah13, Nicholas T. Seyfried 3, Allan I. Levey13 & Thomas S. Wingo 13,14,15
In advanced age, some individuals maintain a stable cognitive trajectory while others
experience a rapid decline. Such variation in cognitive trajectory is only partially explained by
traditional neurodegenerative pathologies. Hence, to identify new processes underlying
variation in cognitive trajectory, we perform an unbiased proteome-wide association study
of cognitive trajectory in a discovery (n= 104) and replication cohort (n= 39) of initially
cognitively unimpaired, longitudinally assessed older-adult brain donors. We ﬁnd 579 pro-
teins associated with cognitive trajectory after meta-analysis. Notably, we present evidence
for increased neuronal mitochondrial activities in cognitive stability regardless of the burden
of traditional neuropathologies. Furthermore, we provide additional evidence for increased
synaptic abundance and decreased inﬂammation and apoptosis in cognitive stability.
Importantly, we nominate proteins associated with cognitive trajectory, particularly the
38 proteins that act independently of neuropathologies and are also hub proteins of protein
co-expression networks, as promising targets for future mechanistic studies of cognitive
trajectory.
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In advanced age, trajectory of cognitive performance over timecan range from stability to rapid decline. Like all complexhuman traits, cognitive trajectory varies from person to
person and is determined by a combination of genetic and
environmental factors including premorbid cognitive abilities,
educational attainment, lifestyle choices, and environmental
exposures1,2. A stable cognitive trajectory in advanced age is
desirable and may reﬂect cognitive resilience, while decline in
cognitive performance may be the earliest manifestation of a
serious neurodegenerative disease1,3. Cognitive decline may ulti-
mately lead to a diagnosis of mild cognitive impairment (MCI) or
dementia. Hence, variation in cognitive trajectory can inﬂuence
onset age for MCI or dementia.
Studying individual cognitive trajectory is strategic for several
reasons. First, it captures all the factors affecting cognition,
including diverse pathologies as well as biological mechanisms
independent of pathologies4–6. Second, it likely captures co-
occurring disease processes and co-occurring age-related
pathologies, which are known to be prevalent in the brains of
aged individuals4,5. Thus, it provides more comprehensive
information than the traditional case/control status based on
clinical or pathological diagnosis. Third, cognitive trajectory is
estimated from periodically and prospectively assessed cognitive
performance. Such trajectory captures the progressive nature of
cognitive decline, from the asymptomatic stage to the manifes-
tation of mild cognitive impairment or dementia, and thus is
more germane to early intervention and prevention. Fourth, as
will be shown, within each category of pathology or clinical
diagnosis of cognitive status, different persons have different
cognitive trajectories making cognitive trajectory relevant to
individuals with or without dementia.
Despite variation in cognitive trajectory, in advanced age the
majority of individuals tend to experience cognitive decline.
Cognitive decline has been suggested to be attributable to
dementia pathologies. However, pathologies such as β-amyloid
plaques, neuroﬁbrillary tangles, microinfarct, macroinfarct, and
Lewy bodies together capture only about 41% of the variance in
cognitive trajectory, leaving 59% unexplained5,7. It is unclear
what causes the large majority of the variance in cognitive tra-
jectory. Proteins, as functional gene products, are well-suited for
studying biological processes underlying individual variation in
cognitive trajectory. Yet, no proteome-wide study of cognitive
trajectory has been performed to date.
To identify biological processes underlying cognitive trajectory,
we here perform an unbiased, large-scale proteome-wide asso-
ciation study of cognitive trajectory using a discovery and repli-
cation cohort of initially cognitively unimpaired, longitudinally
assessed older-adult brain donors (Fig. 1). We then perform gene
ontology enrichment analysis on signiﬁcantly associated proteins
to glean a deeper understanding of the biological processes
underlying individual differences in cognitive trajectory. Next,
we determine which proteins associated with cognitive trajectory
are key drivers of protein co-expression networks because these
proteins are likely promising targets for future mechanistic
studies of cognitive trajectory. Lastly, we determine the proteins
that are associated with cognitive trajectory independently of
the traditional Alzheimer’s disease pathologies (Fig. 1). Together,
our ﬁndings establish a framework for understanding the mole-
cular mechanisms underlying individual differences in cognitive
trajectory.
Results
Subjects. The Banner discovery cohort consisted of 104 partici-
pants who were non-demented at baseline and were followed for
up to 14 years (Table 1). Among these, 48% were women, 27%
had the ﬁnal clinical diagnosis of AD, 73% had the ﬁnal diagnosis
of normal control, and median age at death was 87 (Table 1). The
BLSA replication cohort had 39 participants who were followed
for up to 20 years (Table 1). Of these, 39% were women, 41% had
a ﬁnal clinical diagnosis of AD and 59% had a ﬁnal clinical
diagnosis of normal control, and median age at death was 91
(Table 1).
Personalized cognitive trajectories. The individual cognitive
trajectory was estimated for each participant in both cohorts
(Fig. 2; Table 1; Supplementary Data 1). Cognitive trajectories by
last clinical diagnosis before death and by Braak stage were
depicted in Fig. 2. Trajectories with slopes at or near zero reﬂect
cognitive stability, while trajectories with large negative slopes
indicate faster cognitive decline. We depicted cognitive trajectory
by Braak stage for demonstration here because neuroﬁ-
brillary tangles have been suggested to account for more cognitive
decline than β-amyloid plaques8. The median rate of cognitive
change was −0.3 unit of MMSE score per year for Banner par-
ticipants and −0.1 unit of MMSE per year for BLSA participants
(Table 1). Analyzed jointly, the Spearman’s rank correlation
between cognitive trajectory and clinical diagnosis of cognitive
status was −0.49 (95% conﬁdence interval [CI] of −0.60 to
−0.35, p-value of 4.3 × 10–10) and between cognitive trajectory
and Braak stage was −0.39 (95% CI of −0.51 to −0.24, p-value of
1.5 × 10–6). These data reveal that (i) cognitive trajectory varied
within a given clinical diagnosis or Braak stage; (ii) faster cog-
nitive decline was not exclusively seen in AD cases or in brains
with greater Braak stages; and, (iii) cognitive trajectory provides
complementary information to the clinical diagnosis and neuro-
pathology ﬁndings.
Proteome-wide association study of cognitive trajectory. After
label-free quantiﬁcation, 3710 proteins in Banner cohort and
3933 proteins in BLSA cohort were detected with 10% or fewer
missing values. Among the detected proteins, 2752 protein iso-
forms were detected in both Banner and BLSA cohorts. In the
Banner discovery cohort, 354 proteins were associated with
cognitive trajectory at FDR < 0.05 after adjusting for sex, age at
enrollment, education, age at death, PMI, and batch (N= 104,
Supplementary Data 2; Supplementary Fig. 1A). The top ﬁve
proteins were VGF, SEPT5, DBI, MAPT, and KIAA1045 (aka
PHF24). In the BLSA replication cohort, 127 proteins were
associated with cognitive trajectory at FDR < 0.05 after adjusting
for sex, age at enrollment, education, age at death, and PMI
(N= 39; Supplementary Data 2, Supplementary Fig. 1B). The top
5 proteins were DLD, ABHD10, VDAC1, NDUFV1, and PDHB.
Likely reasons for difference in the top differentially expressed
proteins in the two cohorts are the differences in demographic
composition, follow-up duration, range of cognitive trajectory,
and false discovery. Given these differences, a meta-analysis of
these data was performed to enhance true positive ﬁndings, as the
meta-analysis is designed to integrate the results of several
independent studies and provide a more precise estimate of the
association between predictor and outcome than any individual
study contributing to the pooled analysis9.
The meta-analysis showed 579 proteins associated with
cognitive trajectory in the same directions in both the discovery
and replication cohorts and at FDR < 0.05 among the 2752
protein isoforms commonly detected in both cohorts (N= 143
individuals; Fig. 3a, Supplementary Data 2). Regarding the
direction of association, 350 proteins had increased abundance
while 229 had decreased abundance in cognitive stability.
For instance, VGF protein had increased abundance and
MAPT protein had decreased abundance in cognitive stability
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Fig. 1 Overview of the study design and results. The samples used in this study were from participants in two large prospective studies of aging in the
United States who donated their brains upon death. Each subject in the present study were initially cognitively normal and had antecedent cognitive data
used to estimate personal cognitive trajectories. Whole brain proteomic analysis of dorsolateral prefrontal cortex was used to estimate protein abundance
for each participant. Proteome-wide association study of cognitive trajectory and protein co-expression network analysis revealed that individuals with
cognitive stability (i.e., relatively little decline in cognition over time) have decreased abundance of the proteins involved in inﬂammation and apoptosis but
increased abundance of the proteins involved in mitochondrial activities and synaptic function. Promising protein targets for further study are presented
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(Fig. 3b, c). VGF is a neuropeptide that regulates synaptic
function10, synaptic plasticity11, and hippocampal memory
consolidation12. MAPT (microtubule-associated protein tau) is
involved in axonal transport, synaptic plasticity, and synaptic
function13, and aggregation of hyperphosphorylated tau proteins
can lead to the formation of neuroﬁbrillary tangles and
Alzheimer’s dementia14. Going forward, we will refer to proteins
with increased abundance in cognitive stability as higher-
abundance and proteins with decreased abundance in cognitive
stability as lower-abundance proteins.
Of the 579 cognitive trajectory-associated proteins, we
hypothesized that some would interact potentially as members
of distinct biological processes or organelles. Thus, we asked
whether there was evidence for protein–protein interaction
(PPI) using experimentally validated data available on BioGRID
v3.5.16515. The 569 unique proteins among these 579 proteins
(10 had isoforms) were categorized into presynaptic (N= 159),
postsynaptic (N= 150), both (present in both presynaptic and
postsynaptic density; N= 20), or other (N= 240) using Boyken
et. al. presynaptic list16 and Bayes et. al. postsynaptic density list17
(Supplementary Data 3). Additionally, we labeled any of these
proteins as mitochondrial if they are located in mitochondria
based on Uniprot subcellular location18. Thus, some proteins may
have more than one designation. For instance, of the 157 proteins
designated as mitochondrial, 112 were presynaptic, 10 post-
synaptic, and 35 were other (Supplementary Data 3). For the 569
unique proteins, 484 had at least one PPI, and there were a total
of 2587 PPIs among these 484 proteins (Supplementary Data 3;
Supplementary Fig. 4). Focusing on PPIs emanating from
presynaptic proteins, we found 374 proteins with interactions
(nodes) and 1745 PPIs (edges) (Supplementary Fig. 5A). Focusing
on PPIs originating from postsynaptic proteins, we found 353
proteins with interactions (nodes) and 864 PPIs (edges)
(Supplementary Fig. 5B). Thus there is ample evidence that the
proteins associated with cognitive trajectory interact with each
other and reveal many PPIs within and between presynaptic and
postsynaptic proteins associated with cognitive trajectory. Inter-
estingly, mitochondrial proteins were featured prominently
among cognitive trajectory-associated proteins, and more ﬁnd-
ings about mitochondrial proteins are followed.
Enrichment analysis of cognitive trajectory proteins. To
understand the biological processes related to the 579 proteins
associated with cognitive trajectory, we performed GO enrich-
ment analysis for the 229 proteins with lower-abundance in
cognitive stability and 350 proteins with higher-abundance in
cognitive stability, separately. The lower-abundance proteins were
enriched for inﬂammatory response, apoptosis, endothelial
function, and RNA processing at adjusted p-value < 0.05 by
Fisher’s exact test (Table 2, Supplementary Data 4). The higher-
abundance proteins were enriched for mitochondrial function
and synaptic transmission at adjusted p-value < 0.05 by Fisher’s
exact test (Table 2, Supplementary Data 4). Next, we mapped
these 579 cognitive trajectory-associated proteins to cell types
using brain cell type signatures from Sharma et al.19, Zeisel
et al.20, and Damarnis et al.21. The lower-abundance proteins in
cognitive stability were signiﬁcantly enriched for signatures of
oligodendrocyte, astrocyte, and microglia after multiple testing
correction (Table 2, Supplementary Data 4). The higher-
abundance proteins were strongly enriched for neurons and
mildly enriched for astrocytes at adjusted p-value < 0.05 by
Fisher’s exact test (Table 2, Supplementary Data 4). Together, our
ﬁndings suggest that the 350 proteins with increased abundance
in cognitive stability participate in mitochondrial activities and
synaptic transmission in neurons.
Proteins in cognitive trajectory adjusted for neuropathology.
To determine whether the proteins associated with cognitive
trajectory act through or independently of traditional AD
pathologies, we performed another proteome-wide association
study of cognitive trajectory adjusting for β-amyloid plaque and
neuroﬁbrillary tangle pathology in the discovery and replication
cohort separately, followed by a meta-analysis. At FDR < 0.05, 57
proteins in Banner and 12 proteins in BLSA were associated with
cognitive trajectory after adjusting for sex, age at enrollment,
education, age at death, PMI, β-amyloid plaques, and neuroﬁ-
brillary tangles (Supplementary Data 5). The meta-analysis
revealed 232 proteins associated with cognitive trajectory at
Table 1 Demographic and clinical characteristics of the
discovery and replication cohorts
Characteristic Banner N= 104 BLSA N= 39
Age at enrollment
Mean ± SD 80.7 ± 6.6 74.8 ± 6.9
Median; Range 80.6; [61.5–96.4] 75.3; [58.5–89.3]
Age at death
Mean ± SD 87.0 ± 6.7 87.2 ± 7.7
Median; range 87; [74–103] 91; [71–99]
Sex (% female,
N)
48.1% (50) 38.5% (15)
Education (years)
Mean ± SD 14.6 ± 2.6 16.6 ± 3.0
Median; Range 16; [8.0–20.0] 18; [8.0–20.0]
Clinical diagnosis
AD (%, N) 26.9% (28) 41.0% (16)
Control (%, N) 73.1% (76) 59.0% (23)
Follow-up duration (years)
Mean ± SD 5.1 ± 3.2 9.3 ± 3.9
Median; Range 4.4; [0.5–14.0] 8.5; [3.9–20.4]
PMI (h)
Mean ± SD 2.9 ± 0.9 13.8 ± 5.5
Median; Range 2.7; [1.2–5.5] 14.5; [2.0–24.0]
Braak stage (%, N)
I 4.8% (5) 0% (0)
II 10.6% (11) 15.4% (6)
III 25.0% (26) 15.4% (6)
IV 39.4% (41) 33.3% (13)
V 14.4% (15) 10.3% (4)
VI 5.8% (6) 25.6% (10)
CERAD stage Criteria not met: 12.5%
(13)
0 (none): 20.5% (8)
Deﬁnite AD: 25.0%
(26)
A (sparse): 7.7% (3)
No AD: 28.8% (30) B (moderate): 30.8% (12)
Possible AD: 31.7% (33) C (frequent): 41.0% (16)
Probable AD: 1.9% (2)
Slope of cognitive trajectory (MMSE/year)
All participants
Mean ± SD −0.5 ± 0.8 −0.4 ± 0.6
Median; Range −0.3; [−4.9 to 0.2] −0.1; [−2.4 to 0.1]
By clinical diagnosis (median; range)
Controls −0.1; [−1.6 to 0.2] −0.1; [−0.7 to 0.1]
AD cases −1.1; [−4.9 to −0.1] −0.4; [−2.4 to 0.0]
By Braak stage (median; range)
I and II −0.1; [−0.9 to 0.2] −0.2; [−0.7 to 0.0]
III and IV −0.2; [−2.1 to 0.1] 0.0; [−2.4 to 0.1]
V and VI −1.1; [−4.9 to −0.1] −0.4; [−1.8 to 0.0]
The table summarizes the demographic and clinical characteristics of the Banner (discovery)
and BLSA (replication) cohorts. The following terms Alzheimer’s disease (AD), post-mortem
interval (PMI), Mini-Mental State Exam (MMSE), and Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) are used as acronyms in the table. The underlying data are
available through the Synapse platform (https://www.synapse.org/#!Synapse:syn7170616 and
https://www.synapse.org/#!Synapse:syn3606086) and Supplementary Data 1
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FDR < 0.05 in the same directions in both datasets (Supplemen-
tary Data 5).
To identify biological processes associated with these 232
proteins, GO enrichment analysis was performed on the higher-
abundance and lower-abundance proteins in cognitive stability
separately. Lower-abundance proteins were enriched for the
processes of glycolysis, assembly of neuroﬁlament bundle,
cell–cell adhesion, and RNA binding, and for oligodendrocyte,
astrocyte, and microglia (Table 3; Supplementary Data 6).
Higher-abundance proteins in cognitive stability were enriched
for processes of mitochondrial activities and synaptic transmis-
sion, and for neurons (Table 3; Supplementary Data 6).
Notably, the proteome-wide association study reveals that the
proteins with increased abundance in cognitive stability were
involved in mitochondrial activities and synaptic transmission
in neurons independently of effects of β-amyloid plaques and
neuroﬁbrillary tangles. In addition, the proteins with decreased
abundance in cognitive stability were involved in inﬂammatory
response, apoptosis, and endothelial function in glial cells, likely
acting via β-amyloid plaques and neuroﬁbrillary tangles. In
contrast to the proteins with higher-abundance in cognitive
stability, adjusting for traditional neuropathology inﬂuenced
those with lower-abundance in cognitive stability to a much
greater degree and changed biological processes represented.
Protein co-expression network construction. Many biological
functions require a coordinated effort of a large number of genes
and proteins, and systems biology approaches seek to identify
gene products that act in concert with one another in co-
expression networks22. We identiﬁed 20 modules of strongly co-
expressed proteins in the Banner cohort using WGCNA and then
gleaned the biological processes enriched in these modules with
GO enrichment analysis (Fig. 4; Supplementary Data 7). The ﬁve
largest modules were enriched for synaptic function (M1, 359
proteins), catabolic process and apoptosis (M2, 296 proteins),
mitochondrial function (M3, 276 proteins), myelination (M4, 141
proteins), and transcriptional activities (M5, 83 proteins) at
adjusted p < 0.05 by Fisher’s exact test (Supplementary Data 7).
Of note, our group previously performed a detailed co-expression
network analysis for the BLSA cohort and identiﬁed 16 networks
of co-expressed proteins23. We used these BLSA protein networks
in our subsequent analyses.
We performed a pair-wise overlap analysis between pairs of
Banner and BLSA protein co-expression modules using Fisher’s
exact test. We found nine pairs of signiﬁcant overlap after
multiple testing correction: Banner M1 (synaptic function) with
BLSA M1 (synaptic transmission, ∩= 187 proteins, p= 2.53E
−23, adjusted p= 7.40E−06) and BLSA M4 (synaptic mem-
brane/dendrite, ∩= 59, p= 3.96E−06, adjusted p= 0.0015);
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Fig. 2 Person-speciﬁc cognitive trajectory. This ﬁgure summarizes cognitive trajectory for each individual with colors indicating clinical diagnosis and Braak
stage. Individual cognitive trajectory in the Banner cohort by a last clinical diagnosis (AD or control) prior to death and b Braak stage. Individual cognitive
trajectory in the BLSA cohort by c clinical diagnosis; d Braak stage. A positive slope or small negative slope reﬂects cognitive stability. A larger negative
slope reﬂects faster cognitive decline. The underlying data are available through the Synapse platform (protein abundance, https://www.synapse.org/#!
Synapse:syn7170616 and https://www.synapse.org/#!Synapse:syn3606086) and Supplementary Data 1
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Banner M2 (catabolic process and apoptosis) with BLSA M2
(myelination, ∩= 66, p= 4.27E−06, adjusted p= 0.0017) and
BLSA M6 (inﬂammatory response, ∩= 56, p= 2.28E−08,
adjusted p= 1.54E−05); Banner M3 (mitochondrial function)
with BLSA M3 (mitochondrial function, ∩= 167, p= 5.51E−37,
adjusted p= 7.40E−06); Banner M4 (myelination) with BLSA
M2 (myelination, ∩= 100, p= 5.96E−17, adjusted p= 7.40E
−06), among others (Supplementary Data 7).
Cognitive trajectory proteins and protein networks. The 579
proteins associated with cognitive trajectory from the meta-
analysis were tested for enrichment in each network of co-
expressed proteins in the Banner and BLSA cohorts, respectively.
We considered the 350 higher-abundance proteins and the 229
lower-abundance proteins in cognitive stability separately. The
higher-abundance proteins in cognitive stability were enriched in
modules involved in synaptic function (Banner M1, BLSA M1,
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Fig. 3 Differential protein expression in cognitive trajectory. This ﬁgure summarizes the meta-analysis of the proteome-wide association study of cognitive
trajectory in the discovery (Banner) and replication (BLSA) cohort. a Volcano plot for the meta-analysis of the proteome-wide association studies of
cognitive trajectory in the discovery and replication cohorts. A total of 579 proteins were associated with cognitive trajectory at FDR < 0.05. Among these,
350 proteins had increased abundance and 229 had decreased abundance in cognitive stability. The underlying data are available as Supplementary Data 2.
In b, c, protein abundance vs. slope of cognitive trajectory is plotted with the best-ﬁt regression line drawn in blue and the 95% conﬁdence interval for
the regression line shaded in gray. b Higher VGF protein level was associated with cognitive stability. Of note, for cognitive trajectory, a small negative
slope reﬂects slow decline and a large negative slope reﬂects fast decline. Cognitive stability is reﬂected by a positive slope or very small negative slope
of the cognitive trajectory. c Lower MAPT protein level was associated with cognitive stability. The data underlying b, c are available through the
Synapse platform (protein abundance, https://www.synapse.org/#!Synapse:syn7170616 and https://www.synapse.org/#!Synapse:syn3606086) and
Supplementary Data 1 (cognitive trajectories)
Table 2 Gene ontology and cell-type enrichment analyses for cognitive trajectory-associated proteins
Low-abundance proteins in cognitive stability High-abundance proteins in cognitive stability
GO biological process Inﬂammatory response, apoptosis, endothelial function, RNA processing Mitochondrial function, synaptic transmission
GO cellular component Inﬂammatory response, cellular adhesion Mitochondrion, synaptic vesicle, neuron
GO molecular function RNA binding, cell–cell adhesion Cellular respiration, syntaxin binding
Brain cell type Oligodendrocyte, astrocyte, microglia Neuron, astrocyte
The table summarizes gene ontology (GO) and cell-type enrichment analysis for the 579 cognitive trajectory-associated proteins categorized as either low- or high-abundance in cognitive stability. The
underlying data are provided as a Supplementary Data 4
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and M4) and mitochondrial function (Banner M3 and BLSA M3)
in both cohorts at adjusted p < 0.05 by Fisher’s exact test (Fig. 5a).
On the other hand, the lower-abundance proteins in cognitive
stability were enriched in the modules involved in apoptosis
(Banner M2, BLSA M13), myelination (Banner M4, BLSA M2),
and inﬂammatory response (BLSA M6 and indirectly Banner
M2 by virtue of overlap) in both cohorts at adjusted p < 0.05 by
Fisher’s exact test (Fig. 5b).
Among the 232 proteins associated with cognitive trajectory
independently of β-amyloid plaques and neuroﬁbrillary tangles,
we found that the higher-abundance proteins in cognitive
stability were enriched for modules of synaptic function (Banner
M1, BLSA M1, and BLSA M4), and mitochondrial function
(Banner M3 and BLSA M3) in both cohorts at adjusted p < 0.05
by Fisher’s exact test (Fig. 5c). The lower-abundance proteins in
cognitive stability were enriched for the modules involving
apoptosis (Banner M2, BLSA M13), myelination (Banner M4,
BLSA M2), and inﬂammatory response (BLSA M6 and Banner
M2 by virtue of overlap) in both cohorts at adjusted p < 0.05
by Fisher’s exact test (Fig. 5d).
We note that through both approaches—proteome-wide
association study of cognitive trajectory and protein co-
expression networks—we found consistent results that the over-
expressed proteins in cognitive stability were enriched for
mitochondrial activities and synaptic function independently of
β-amyloid plaques and neuroﬁbrillary tangles.
Modules of co-expressed proteins and cognitive trajectory. We
examined direct correlation between the modules of co-expressed
proteins and cognitive trajectory in each cohort. In the Banner
network, 10 of its 20 modules were associated with cognitive
trajectory at FDR < 0.05 (Table 4). The top six of these 10
modules were the same modules found to be enriched among
the proteins associated with cognitive trajectory (Table 4, Fig. 5a).
In BLSA, four modules were associated with cognitive trajectory
at by linear regression p < 0.05 but only one remained sig-
niﬁcantly associated with cognitive trajectory after adjusting for
multiple testing (M3/mitochondrial function, p= 0.0025, adjus-
ted p= 0.039), likely due to small sample size and thus lower
power (Table 4).
After adjusting for β-amyloid plaques and neuroﬁbrillary
tangles by linear regression, only two of the Banner modules M1/
Synaptic function (β= 0.039, p= 6.74E−06, adjust p= 0.00013)
and M2/Catabolic processes and apoptosis (β=−0.032, p=
3.02E−05, adjust p= 0.00030) remained signiﬁcantly associated
with cognitive trajectory after multiple testing adjustment at FDR
< 0.05. For BLSA, only one module, M3/mitochondrial function
(β=−0.097, p= 0.0059, adjust p= 0.095), was associated with
cognitive trajectory at adjusted p-value < 0.1 by linear regression
after adjusting for β-amyloid plaques and neuroﬁbrillary tangles.
Cognitive trajectory-associated proteins and hub proteins. In
protein co-expression networks, hub proteins are likely important
proteins because they are highly correlated with other proteins in
the module. We sought to determine whether proteins associated
with cognitive trajectory were also hub proteins in the Banner and
BLSA co-expression networks. Hub proteins were deﬁned as
proteins with intramodular kME in the top 90th percentile. We
focused on the seven Banner and seven BLSA modules that the
579 cognitive trajectory-associated proteins were enriched in
(Fig. 5). In Banner, these seven modules had 123 hub proteins, of
which 102 (83%) were associated with cognitive trajectory
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Fig. 4 Protein co-expression network. This ﬁgure shows the WGCNA cluster dendogram and 20 distinct protein co-expressed modules deﬁned by
dendogram branch cutting in the Banner cohort. Each module is given in a box with the module number and a functional summary of the proteins in the
module derived by gene ontology enrichment. The underlying data are provided as a Supplementary Data 7
Table 3 Gene ontology and cell type enrichment analyses of cognitive trajectory-associated proteins adjusting for
neuropathology
Low-abundance proteins in cognitive stability High-abundance proteins in cognitive stability
GO biological process Glycolysis, neuroﬁlament bundle assembly Mitochondrial activities, synaptic transmission
GO cellular component Focal adhesion, axon, neuroﬁbrillary tangle, microtubule Mitochondrion, synaptic vesicle
GO molecular function RNA binding, cell–cell adhesion Syntaxin binding
Brain cell type Oligodendrocyte, astrocyte, microglia Neuron
The table summarizes gene ontology (GO) and cell-type enrichment analysis for the 232 cognitive trajectory-associated proteins adjusting for β-amyloid and neuroﬁbrillary tangle pathology.
Differentially abundant proteins are categorized as either low- or high-abundance in cognitive stability. The underlying data are provided as a Supplementary Data 6
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(Supplementary Data 8). In BLSA, among the 131 hub proteins in
the seven modules, 99 (76%) were associated with cognitive tra-
jectory (Supplementary Data 8). We performed the same analysis,
except that the input proteins were those that associate with
cognitive trajectory independently of pathologies. We found that
among the 123 hub proteins in Banner and 127 hub proteins in
BLSA, 67 and 62 respectively were also associated with cognitive
trajectory independently of β-amyloid plaques and
neuroﬁbrillary tangles (Supplementary Data 8). In common
between these 67 (Banner) and 62 (BLSA) hub and cognitive
trajectory-associated proteins were 38 proteins (Table 5, Supple-
mentary Data 8). Notably, these 38 proteins were associated with
cognitive trajectory independently of β-amyloid plaques and
neuroﬁbrillary tangles in both Banner and BLSA, and were also
hub proteins in both Banner and BLSA and thus are tractable
targets for further mechanistic studies of cognitive stability.
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Fig. 5 Modules enriched for cognitive trajectory-associated proteins. This ﬁgure summarizes the protein co-expression modules that are enriched for
cognitive trajectory-associated proteins for each cohort with and without adjustment for neuropathologies. Enrichment was determined by Fisher’s exact
test and reported p-values are adjusted for FDR. There are 579 cognitive trajectory-associated proteins in Banner and BLSA cohorts, which were divided
into lower-abundance proteins in cognitive stability (229 proteins, colored in salmon) and higher-abundance proteins in cognitive stability (350 proteins,
colored in turquoise), respectively. a Banner protein module enrichment; b BLSA protein module enrichment. After adjusting for β-amyloid plaques and
neuroﬁbrillary tangles, there were 232 cognitive trajectory-associated proteins, and enrichment was performed separately for lower-abundance proteins in
cognitive stability (81 proteins, colored in salmon) and higher-abundance proteins in cognitive stability (151 proteins, colored in turquoise), respectively.
c Banner protein module enrichment; d BLSA protein module enrichment. Source data are provided as a Source Data ﬁle
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Remarkably, the top protein of this 38-protein list is DLG4,
also known as PSD95, which is one of the most abundant scaffold
proteins at the excitatory brain synapses and known to affect
brain development, neuronal plasticity, memory and learning,
and overall cognitive function24–28. We asked whether proteins
known to interact with PSD95, i.e., PSD95 interactome, were
also associated with cognitive trajectory using the published
PSD95 interactome from Fernandez et al.24. Among the 118
proteins known to interact with PSD95, 109 were detected in
the Banner cohort. The ﬁrst principal component of these 109
proteins, which captures 99.3% of the variance of the PSD95
interactome, was signiﬁcantly associated with cognitive trajectory
by linear regression (β= 0.016; p= 0.0001; N= 104; Supplemen-
tary Fig. 6). This implies that higher expression of the PSD95
interacting partners was associated with cognitive stability
(Supplementary Fig. 6).
Discussion
We performed an unbiased proteome-wide association study
of cognitive trajectory in a discovery and replication cohort, fol-
lowed by a meta-analysis, to identify biological processes under-
lying cognitive stability. Particularly, we used both proteome-
wide differential analysis and protein co-expression network
analysis to gain insights into changes in individual proteins as
well as networks of proteins in cognitive trajectory. Our most
notable ﬁnding is that proteins involving mitochondrial activities
or synaptic functions had increased abundance among indivi-
duals with cognitive stability regardless of the burden of β-
amyloid plaques or neuroﬁbrillary tangles. In other words,
cognitive stability is associated with increased mitochondrial
and synaptic activities independently of the burden of β-amyloid
plaques or neuroﬁbrillary tangles in neurons predominantly.
These ﬁndings were derived from two approaches in two different
cohorts: (i) proteome-wide association study of cognitive trajec-
tory followed by GO enrichment analysis of the associated
proteins, and (ii) protein co-expression network enrichment
analysis of the cognitive trajectory-associated proteins. Most
interestingly, mitochondrial activities are strikingly present in
our analysis in a way not seen when considering the clinical
diagnosis of cognitive status or AD pathologic outcomes. For
instance, BLSA module M3, enriched for mitochondrial function,
was most signiﬁcantly associated with cognitive trajectory both
before and after adjusting for plaques and tangles. This module
was not signiﬁcantly associated with clinical diagnosis or AD
pathologies after multiple testing correction in our previous
publication23, suggesting that cognitive trajectory captures bio-
logical processes that are independent of traditional AD
pathologies.
Mitochondria in neurons are crucial for maintaining synaptic
function, and most of the mitochondrial proteins are encoded in
the nuclear genome29. In the brain, mitochondria regulate
synaptic transmission by generating ATP to power the process
and by modulating presynaptic calcium level, which in turn
determines the release of neurotransmitters29. Synaptic mito-
chondria, therefore, are vital for the maintenance of synaptic
function and transmission29–31. This is consistent with our
ﬁnding that 157 proteins of the 579 cognitive trajectory-
associated proteins are mitochondrial proteins and of these, 122
are located in the mitochondria either in the pre- or postsynaptic
density. Mitochondrial dysfunction has been suggested to occur
early in the progression to AD and continues into later stages of
AD31–34. An example of early manifestation of mitochondrial
dysfunction is a study of expired young-adult APOE4 carriers vs.
expired young-adult non-APOE4 carriers32. In that study, young-
adult participants in both groups did not have amyloid or tangle
deposition in the posterior cingulate cortex (PCC); yet, APOE4
carriers, i.e., those at greater risk for developing AD, showed
reduced mitochondrial activity in PCC neurons, as measured by
cytochrome oxidase levels, suggesting that a change in mito-
chondrial function may be the earliest manifestation of AD risk32.
An example of mitochondrial dysfunction continuing into later
stages of AD is a transcriptomic study of post-mortem brain of
AD cases and controls in the PCC and other brain regions33. This
study found that the nuclear genes encoding the mitochondrial
electron transport chain subunits had decreased expression in
AD cases compared to controls in PCC and other brain regions33.
Furthermore, a transgenic mouse model showed that amyloid
pathology, even at a low level, can induce deﬁcits in the func-
tioning of synaptic mitochondria leading to synaptic degenera-
tion30. Synaptic degeneration has been suggested to be one of the
earliest cellular event in AD pathogenesis, and synaptic loss to
be the best correlate of cognitive impairment in AD (see review
by Reddy et al.31). These ﬁndings are consistent with ours. Here,
we show proteins involved in mitochondrial activities had lower-
abundance in persons with faster cognitive decline but higher-
abundance in persons with cognitive stability in an unbiased
human proteome-wide study. Taken together, our ﬁndings and
others highlight that mitochondrial activities would be a fruitful
research target for early prevention of cognitive decline and
enhancement of cognitive stability.
Table 4 Correlations between modules of co-expressed proteins and cognitive trajectory
Module Biological process r p-value Adjusted p-value
BANNER (N= 104) M1 Synaptic function 0.52 1.52E−08 1.52E−07
M3 Mitochondrial function 0.39 3.73E−05 0.00019
M2 Catabolic process and apoptosis −0.59 4.15E−11 8.30E-10
M13 CNS structure morphogenesis −0.41 1.45E−05 9.66E−05
M4 Myelination −0.34 0.000329 0.00132
M7 RNA processing and translation −0.32 0.000847 0.00282
M14 Response to unfolded protein −0.26 0.00758 0.0217
M16 Cell–cell interaction −0.24 0.0121 0.0270
M6 Ion transport −0.24 0.0144 0.0288
M11 Intracellular transport 0.25 0.0097 0.0243
BLSA (N= 35) M3 Mitochondrial function 0.50 0.0025 0.039
M4 Synaptic membrane/dendrite 0.40 0.0180 0.085
M6 Inﬂammatory response −0.39 0.0189 0.085
M8 Ribonucleoprotein complex −0.39 0.0214 0.085
The table summarizes the Pearson correlation (r) between modules of co-expressed proteins and cognitive trajectory. The underlying data are available through the Synapse platform (https://www.
synapse.org/#!Synapse:syn7170616 and https://www.synapse.org/#!Synapse:syn3606086) and Supplementary Data 1
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Synaptic function in cognitive decline has been given more
attention than the mitochondrial function. For instance, a study
of candidate synaptic proteins in cognitive decline in AD found
that reduced abundance of the synaptic protein SNAP25 was
associated with faster cognitive decline35. Consistently, in both
Banner and BLSA, we found that lower-abundance of SNAP25
was associated with faster cognitive decline. Furthermore,
Bereczki and colleagues performed a comprehensive study of
851 synaptic proteins in neurodegenerative diseases and cognitive
decline36. They found that reduced levels of synaptic proteins
SNAP47, SYBU, LRFN2, SV2C, and GRIA3 were associated with
cognitive impairment and faster cognitive decline36. Among these
proteins, only GRIA3 was detected in our datasets and had lower-
abundance in faster cognitive decline in both Banner and BLSA,
consistent with Bereczki and colleagues’ ﬁnding.
The next notable ﬁnding is the 38 proteins that were associated
with cognitive trajectory independently of typical AD neuro-
pathologies and were also hub proteins in both Banner and BLSA
protein networks. These proteins are highly promising targets for
future mechanistic studies of cognitive trajectory. Among these 38
proteins, those that are higher-abundance in cognitive stability
are involved in either mitochondrial activities or synaptic
function, and those with lower-abundance in cognitive stability
are involved in myelination or apoptosis. Among the proteins
involved in synaptic function is DLG4, also known as PSD-95
(postsynaptic density-95 protein). PSD-95 is a major scaffold
protein of the dendritic spines and its expression level has been
shown to be altered in aging, AD, and several psychiatric dis-
orders37. PSD-95 is important for neuronal plasticity and mem-
ory consolidation via its regulation of synaptic glutamate
receptors, signaling proteins, adhesion molecules, and cytoskeletal
proteins37,38. Here we show that the aggregate of PSD-95 inter-
actome abundance is also associated with cognitive trajectory.
Bustos and colleagues showed that increased protein level of
PSD95 in the hippocampus rescued memory deﬁcits of aged mice
and dementia mice38. Their ﬁnding is consistent with ours in
which overexpression of PSD95 protein was associated with
cognitive stability. The second protein on the list, SYT1, was
found to have reduced abundance in AD39. Overexpression of
Syt1 in mouse hippocampi was found to promote protective
presenilin-1 conformation39, consistent with our ﬁnding of its
protective effect. Another protein on this list, HOMER1 (i.e.,
HOMER1a) is an important protein for synaptic plasticity
and memory consolidation because it drives homeostatic
Table 5 Co-expression hub proteins associated with cognitive trajectory
Protein Function Effect size Adjusted P-value Direction
DLG4|P78352-3 Synaptic function 1.6554 0.00016497 ++
SYT1|P21579 Synaptic function 1.5316 0.00026653 ++
HOMER1|Q86YM7 Synaptic function 1.2889 0.00040777 ++
BAIAP2|Q9UQB8-3 Synaptic function 1.5948 0.00042608 ++
ATP6V0D1|P61421 Synaptic function 1.4719 0.0004631 ++
SLC30A3|Q99726 Synaptic function 0.6046 0.00090009 ++
GRIA2|P42262 Synaptic function 1.3181 0.00174731 ++
DMXL2|Q8TDJ6 Synaptic function 1.5595 0.00214875 ++
SLC17A7|Q9P2U7 Synaptic function 1.1304 0.00419658 ++
ATP6V0A1|Q93050-1 Synaptic function 1.3017 0.00520941 ++
SYNPO|Q8N3V7-3 Synaptic function 0.5984 0.0054183 ++
ANKS1B|Q7Z6G8-3 Synaptic function 0.9659 0.00597171 ++
AP2B1|P63010 Synaptic function 1.7094 0.01001969 ++
SEPT11|D6RGI3 Synaptic function 1.8515 0.01278615 ++
BSN|Q9UPA5 Synaptic function 0.957 0.01474302 ++
AP2A2|O94973 Synaptic function 1.5492 0.01679196 ++
STX1A|Q16623 Synaptic function 0.9072 0.02188469 ++
AP2A1|O95782-2 Synaptic function 1.6634 0.03793744 ++
HSPA2|P54652 Myelination −0.822 0.00140989 −−
NEFL|P07196 Myelination −0.5826 0.00746409 −−
NEFM|E7ESP9 Myelination −0.5688 0.01161255 −−
MBP|P02686 Myelination −0.3966 0.01545858 −−
CNP|P09543 Myelination −0.4468 0.02383309 −−
PDHA1|P08559 Mitochondrial function 1.7283 0.00020668 ++
TUFM|P49411 Mitochondrial function 1.7968 0.00346194 ++
NDUFV1|P49821-2 Mitochondrial function 1.2578 0.0036826 ++
NNT|Q13423 Mitochondrial function 1.7308 0.00433757 ++
NDUFS1|P28331 Mitochondrial function 1.2152 0.00693232 ++
NDUFS2|O75306 Mitochondrial function 1.1988 0.00815356 ++
NDUFA10|A0A087WXC5 Mitochondrial function 1.2738 0.01359488 ++
NDUFA9|Q16795 Mitochondrial function 1.0601 0.02221231 ++
UQCRFS1|P47985 Mitochondrial function 1.076 0.02672126 ++
ACO2|Q99798 Mitochondrial function 1.3845 0.04333576 ++
NDUFS5|O43920 Mitochondrial function 0.876 0.04357237 ++
LLGL1|Q15334 Catabolic process and apoptosis −0.7602 0.02131939 −−
GSN|P06396-2 Catabolic process and apoptosis −0.6694 0.02687423 −−
GFAP|P14136 Catabolic process and apoptosis −0.3761 0.03997317 −−
LMNA|P02545 Catabolic process and apoptosis −0.7264 0.04584879 −−
This table summarizes 38 hub proteins that were associated with cognitive trajectory after adjusting for β-amyloid plaques and neuroﬁbrillary tangles and their Pearson correlation with cognitive
trajectory. The p-values are from the meta-analysis of the proteome-wide association studies of cognitive trajectory adjusting for β-amyloid plaques and neuroﬁbrillary tangles from Supplementary
Data 5. The underlying data are available through the Synapse platform (https://www.synapse.org/#!Synapse:syn7170616 and https://www.synapse.org/#!Synapse:syn3606086) and Supplementary
Data 1
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scaling-down of excitatory synapses during sleep to remodel
synapses and consolidate contextual memory40. Consistently, we
found that the protein level of HOMER1 was increased in cog-
nitive stability. SLC30A3, aka ZNT3, is a synapse-speciﬁc vesi-
cular zinc transporter that is important for zinc homeostasis and
required for hippocampus-dependent memory41. Consistently,
we found that SLC30A3 protein level was increased in cognitive
stability. SLC17A7, aka VGLUT1, is a sodium-dependent phos-
phate transporter that is speciﬁcally expressed in the neuron-rich
regions of the brain and transports glutamate. Decreased abun-
dance of this protein can lead to susceptibility to neuroin-
ﬂammation and disruption of synaptic plasticity42. Along the
same theme, SYNPO has been found to be important for synaptic
plasticity43,44. A notable theme among the proteins participating
in synaptic function on this list of 38 proteins is that they are
important for neuronal plasticity and memory consolidation and
their overexpression is associated with cognitive stability.
Some proteins, including NEFM and MBP, participate in
myelination on this list of 38 proteins. Myelination refers to the
formation of a membranous sheath surrounding axons to
increase signal transmitting speed between neurons and is not
limited to early development but occurs throughout adulthood45.
NEFM are neuroﬁlaments that maintain neuronal caliber and
participate in intracellular transport to axons and dendrites.
NEFM was shown to accumulate in the hippocampus in the
presence of amyloid pathology46. To retard human aging and age-
related diseases, inhibition of insulin-like growth factor 1 (IGF1)
has been proposed, and several studies have shown that neuron-
speciﬁc deletion of IGF1R confers neuroprotection and improves
behavior in AD transgenic mice46–48. From a genome-wide
screen, a prominent observation after genetic ablation of IGF1
receptor in AD mice is the reduction in expression level of
NEFM, down to control level, suggesting that lower-abundance of
NEFM is protective46. These ﬁndings are consistent with ours, in
which lower-abundance of NEFM was associated with cognitive
resilience. Myelin basic protein, MBP, can inﬂuence β-amyloid
accumulation in the brain. Indeed, deletion of MBP gene led to a
signiﬁcant reduction in cerebral β-amyloid levels in Tg-3xFAD
mice49, consistent with our ﬁnding of decreased abundance of
MBP being associated with cognitive stability.
Besides the 38 proteins above, we also presented (i) 579 pro-
teins associated with cognitive trajectory from our meta-analysis,
(ii) 232 proteins associated with cognitive trajectory indepen-
dently of amyloid plaques and neuroﬁbrillary tangles, (iii) 102
proteins and 99 proteins associated with cognitive trajectory and
were also hub proteins in Banner networks and BLSA networks,
respectively. Furthermore, we note that VGF is strongly asso-
ciated with cognitive trajectory with or without adjusting for AD
neuropathology. VGF is also a hub protein for Banner M1
module, which involves synaptic function. Our ﬁndings suggest
that VGF likely act through mechanisms independent of β-
amyloid plaques and neuroﬁbrillary tangles in contributing to
cognitive decline. VGF is a neuropeptide that promotes hippo-
campal neurogenesis, dendritic maturation, and synaptic activ-
ity50. VGF is induced by BDNF and serotonin and is upregulated
by antidepressants, exercise, and is reduced in animal models of
depression51. VGF is another promising candidate for the
mechanistic study of cognitive stability, consistent with ﬁndings
from this multiscale causal network modeling of AD52.
From the protein co-expression network analysis, we found 10
Banner protein modules and 1 BLSA protein module associated
with cognitive trajectory. Fewer networks remained associated
with cognitive trajectory after adjusting for β-amyloid plaques
and neuroﬁbrillary tangles, suggesting that some networks act
through pathology while others act independently of pathology to
contribute to variation in cognitive trajectory. We also note that
the published BLSA protein co-expression modules used here
were constructed using the protein expression levels from both
the dorsolateral prefrontal cortex (dPFC) and precuneus so the
module memberships might be slightly different than those from
the dPFC alone. On the other hand, proteins and protein co-
expression networks that are consistently changed within the two
regions likely reﬂect biologically meaningful differences.
We found cognitive trajectory-associated proteins to be enri-
ched in astrocytes, which perform important roles for neural
functioning. Astrocytes provide neurotrophic support to promote
neuronal survival, are important in the formation and maturation
of synapses, help control neurotransmitter concentrations, and
play a role in maintaining the blood-brain barrier53. We found
that both higher- and lower-abundance proteins in cognitive
stability were enriched in astrocytes. Our ﬁndings may reﬂect the
two types of astrocytes as described in the literature—reactive
astrocytes that lose the ability to promote neuronal survival,
outgrowth, and synaptogenesis, and induce death of neurons and
oligodendrocytes, and homeostatic astrocytes that promote neural
functioning54.
Our ﬁndings should be interpreted in light of the strengths and
limitations of this study. First, this is an association study and
thus it precludes causal inference. However, we nominated the
tractable targets for further mechanistic studies of cognitive tra-
jectory. Second, our label-free proteomic method yielded
approximately 3900 proteins in the proteome, which is not as
comprehensive of a proteomic proﬁle as would be ideal, and
larger proteomic analysis will undoubtedly add reﬁnement to the
proteins and protein networks involved in cognitive trajectory.
Third, the available cognitive data was from the MMSE, a widely
used screening tool that provides a coarse gauge of cognitive
performance. Nevertheless, the decline in MMSE generally par-
allels that of more detailed testing55. Fourth, our sample sizes are
relatively small (n= 104 and n= 39) and exclusively Caucasians,
which may limit the generalizability of our ﬁndings and power.
Despite this, ours is the largest brain proteomic study of cognitive
trajectory to our knowledge. These subjects were followed for a
total of 887 person-years over 676 visits. We also employed a
discovery and replication cohort design followed by meta-analysis
to reduce false positive ﬁndings. Furthermore, our focus on
individual cognitive trajectory is more germane to early inter-
vention and precision medicine. Finally, our ﬁndings establish a
framework for understanding mechanisms underlying cognitive
trajectory and nominate a list of highly promising targets for
future mechanistic studies of cognitive stability.
Methods
Banner sun health research institute participants. This project, the Arizona
Study of Aging and Neurodegenerative Disorders, is a longitudinal clin-
icopathological study of normal aging, Alzheimer’s disease (AD), and Parkinson’s
disease (PD)56. Most subjects were enrolled as cognitively unimpaired volunteers
from the retirement communities of the greater Phoenix, Arizona, USA56.
Recruitment efforts were also directed at subjects with AD and PD from the
community and neurologists’ ofﬁces. Subjects received standardized general
medical, neurological, and neuropsychological tests annually during life and more
than 90% received full pathological examinations after death56. For this study, we
only included subjects with a clinical diagnosis of AD or normal control rendered
approximate to death. Please refer to Table 1 for subject characteristics. Additional
inclusion criteria for this study were having a baseline score from the Mini Mental
State Examination (MMSE) of 27 or above (i.e., non-demented at baseline)57,58 and
at least one additional MMSE score in subsequent follow-up visits. All enrolled
subjects in the Banner dataset or their legal representatives sign a Banner Sun
Health Research Institute Institutional Review Board-approved informed consent
form allowing both clinical assessments during life, several options for brain and/or
bodily organ donation after death, and usage of donated biospecimens for
approved future research56.
Baltimore Longitudinal Study of Aging (BLSA) participants. BLSA is a pro-
spective cohort study of aging in community-dwelling individuals59,60. It
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continuously recruits healthy volunteers aged 20 or older and follow them for life
regardless of changes in health or functional status. Participants were examined
at the National Institute of Aging Clinical Research Unit in Baltimore at one to
four-year intervals, with more frequent follow-up visits for older participants59,60.
Due to a smaller sample size and the fact that these subjects were recruited as
cognitively unimpaired individuals, all BLSA individuals with proteomic data were
included regardless of MMSE score at baseline. The BLSA study was approved
by the Institutional Review Board and the National Institute on Aging. Human
research at the National Institutes of Health (NIH) is implemented in accord with
the U.S. Department of Health and Human Services (45 CFR46) and U.S. Food and
Drug Administration (21 CFR 50 and 56) regulations for the protection of human
subjects. The NIA IRB is part of the Human Subject Protection Program of the
NIH. All BLSA participants provided written informed consent at each visit61.
Personalized cognitive trajectory. Person-speciﬁc cognitive trajectory was esti-
mated using a linear mixed model for each subject. For each cohort, we model the
annual MMSE score as a longitudinal outcome, follow-up year as the independent
variable and sex, age at enrollment, and education as the covariates, with a random
intercept and random slope per subject using the lme4 R package (version 1.1-19).
The derived cognitive trajectory for each individual in Banner and BLSA cohorts is
listed in Supplementary Data 1.
Pathological assessment of Banner and BLSA cohorts. Measures of AD
pathology, i.e., β-amyloid plaques and neuroﬁbrillary tangles, were used as cov-
ariates to adjust for the degree of AD pathology in each sample. Beach et al.
described in detail how these measures were derived for the Banner cohort56.
Brieﬂy, plaque total is the summary density score of all types of amyloid plaques in
the frontal, temporal, and parietal cortices, as well as hippocampus CA1 region and
entorhinal region. Additionally, neuritic plaque density scoring was done according
to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)58.
Tangle total is the sum of neuroﬁbrillary tangle density in the frontal cortex,
temporal cortex, parietal cortex, hippocampus, and entorhinal region. Tangle
scoring was done according to the CERAD templates58. In the BLSA cohort,
O'Brien et al. described how estimates of β-amyloid positive plaques and neuro-
ﬁbrillary tangles were derived62. Brieﬂy, silver staining was performed to assess the
severity of neuritic plaques using CERAD stage (range: 0–3) and of neuroﬁbrillary
tangles using Braak stage (range: 1–6), with higher scores indicating higher level
of severity.
Proteomic measurements. Proteomic quantiﬁcation for both cohorts used the
approach described in detail in Seyfried et al.23 and enumerated below. For both
cohorts, whole-brain proteomes were derived from cortically dissected dorsolateral
prefrontal cortex for the discovery and replication cohorts, separately. Approxi-
mately 100 mg of tissue was combined with 500 μL of urea lysis buffer (8 M urea,
100 mM NaHPO4, pH 8.5) and 5 μL (100× stock) HALT protease and phosphatase
inhibitor cocktail (Pierce) in a 1.5 mL Rino tube (Next Advance) with a 750 mg
stainless steel bead (0.9–2 mm in diameter). Homogenization was performed using
a Bullet Blender (Next Advance) at 4 °C with two 5-min intervals of blending.
Supernatant was transferred to 1.5 mL Eppendorf tube and sonicated (Sonic Dis-
membrator, Fisher Scientiﬁc) 3 times for 5 s with 15 s intervals of rest at 30%
amplitude to disrupt nucleic acids and subsequently vortexed. Protein concentra-
tion was determined by the bicinchoninic acid (BCA) method, and samples were
frozen in aliquots at −80 °C. Each homogenate was analyzed by SDS-PAGE to
assess for protein integrity. Protein homogenates (150 μg) were diluted with 50 mM
NH4HCO3 to a ﬁnal concentration of less than 2M urea and then treated with 1
mM dithiothreitol (DTT) at 25 °C for 30 min, followed by 5 mM iodoacetimide
(IAA) at 25 °C for 30 min in the dark. Protein was digested with 1:100 (w/w) lysyl
endopeptidase (Wako) at 25 °C for 2 h and further digested overnight with 1:50 (w/
w) trypsin (Promega) at 25 °C. Resulting peptides were desalted with a Sep-Pak
C18 column (Waters) and dried under vacuum. For quantiﬁcation, peptides (2 μg)
were resuspended in peptide loading buffer (0.1% formic acid, 0.03% triﬂuoroacetic
acid, 1% acetonitrile) containing 0.2 pmol of isotopically labeled peptide calibrants
(Life Technologies, #88321). Peptide mixtures were separated on a self-packed C18
(1.9 um Dr. Maisch, Germany) fused silica column (25 cm × 75 uM internal dia-
meter (ID); New Objective, Woburn, MA) by a NanoAcquity UHPLC (Waters,
Milford, FA) and monitored on a Q-Exactive Plus mass spectrometer (Thermo-
Fisher Scientiﬁc, San Jose, CA). For the Banner cohort, elution was performed over
a 120-min gradient at a rate of 275 nL/min with buffer B ranging from 3 to 60%
(buffer A: 0.1% formic acid and 5% DMSO in water, buffer B: 0.1% formic and 5%
DMSO in acetonitrile). For the BLSA cohort, elution was also performed over a
120-min gradient but at a rate of 250 nL/min with Buffer B ranging from 3 to 80%
(buffer A: 0.1% formic acid in water, buffer B: 0.1% formic acetonitrile). For both
cohorts, the mass spectrometer cycle was programmed to collect one full MS scan
followed by 10 data-dependent MS/MS scans. The MS scans (300–1800m/z
range,1,000,000 AGC, 100 ms maximum ion time) were collected at a resolution of
70,000 at m/z 200 in proﬁle mode and the MS/MS spectra (2m/z isolation width
with 0.5m/z offset, 30% collision energy, 50,000 AGC target, 50 ms maximum ion
time) were acquired at a resolution of 17,500 at m/z 200. Dynamic exclusion was
set to exclude previously sequenced precursor ions for 30 s within a 10 ppm
window. Precursor ions with +1, and +6 or higher charge states were excluded
from sequencing.
MaxQuant (v1.5.3.30 for Banner cohort and v1.5.2.8 for BLSA cohort) with
Thermo Foundation 2.0 for RAW ﬁle reading capability was used to generate label-
free quantiﬁcation. The search engine Andromeda, integrated into MaxQuant 1,
was used to build and search a concatenated target-decoy IPI/Uniprot human
reference protein database (retrieved April 20, 2015; 90,411 target sequences), plus
245 contaminant proteins from the common repository of adventitious proteins
(cRAP) built into MaxQuant. Methionine oxidation (+15.9949 Da), asparagine and
glutamine deamidation (+0.9840 Da), and protein N-terminal acetylation
(+42.0106 Da) were variable modiﬁcations (up to 5 allowed per peptide); cysteine
was assigned a ﬁxed carbamidomethyl modiﬁcation (+57.0215 Da). Only fully
tryptic peptides were considered with up to 2 miscleavages in the database search.
A precursor mass tolerance of ± 20 ppm was applied prior to mass accuracy
calibration and ± 4.5 ppm after internal MaxQuant calibration. Other search
settings included a maximum peptide mass of 6000 Da, a minimum peptide length
of 6 residues, 0.05 Da tolerance for high resolution MS/MS scans. Co-fragmented
peptide search was enabled to deconvolute multiplex spectra. The false discovery
rate (FDR) for peptide spectral matches, proteins, and site decoy fraction were all
set to 1 percent. Quantiﬁcation settings were as follows: requantify with a second
peak ﬁnding attempt after protein identiﬁcation has completed; match MS1 peaks
between runs; a 0.7 min retention time match window was used after an alignment
function was found with a 20-min RT search space. The quantitation method only
considered razor plus unique peptides for protein level quantitation. Options to
access the full list of parameters used for MaxQuant, raw and searched proteomic
data are described in the Data Availability section. In our prior work on the BLSA
dataset, we used data from the dorsolateral prefrontal cortex (dPFC) and precuneus
regions together; however, in this work, we only focused on proteins from the
dPFC. After label-free quantiﬁcation, 3710 protein groups in Banner and 3933
protein groups in BLSA cohorts were detected, and 2752 protein isoforms were
detected in both Banner and BLSA cohorts.
Proteomic quality control. Only proteins quantiﬁed in at least 90% of the samples
were included in the analysis. We performed log2 transformation of the proteomic
proﬁles. Subsequently, linear mixed models from the R package variancePartition63
were used to characterize the percent of protein variance explained by biological
and technical variables. This approach was used to quantify the main sources of
variation in each proteomic dataset separately and identiﬁed the variance attri-
butable to age, sex, neuropathology, post-mortem interval (PMI), and batch. For
instance, in the Banner cohort, batch and sex explained substantial proportions
while age at death and PMI explained some proportions of variance of the pro-
teomic proﬁle (Supplementary Fig. 2). Therefore, within each cohort, effect of
batch was removed using Combat64, and effects of sex, age at death, and PMI were
removed using bootstrap regression. We removed these technical (batch and PMI)
and biological effects (sex and age at death) because they may confound our
association analyses between cognitive trajectory and protein levels. Supplementary
Fig. 3 shows that after Combat and bootstrap regression, batch, sex, age at death,
and PMI explained only minimal amounts of the variance of the proteomic proﬁle.
The same approach was used to successfully remove the effects of these same
covariates from the BLSA proteome23.
Proteome-wide association study of cognitive trajectory. Proteome-wide
association analysis was performed in each cohort separately, and meta-analysis
was used to combine individual results. In each cohort, linear regression was
performed with cognitive trajectory as the outcome and normalized protein
abundance as the predictor. In our planned secondary analysis, we performed the
same association analysis as above but adding β-amyloid plaques and neuroﬁ-
brillary tangles as covariates. Meta-analysis was performed with METAL65, a
popular meta-analysis tool66, using effect size estimates and standard errors from
the proteome-wide association studies of cognitive trajectory in Banner and BLSA,
respectively. We included proteins that are detected in both the Banner and BLSA
cohorts in the meta-analysis. For all analyses, we used Benjamini–Hochberg (BH)
method to control the false discovery rate (FDR)67, and declared signiﬁcantly
associated proteins as those with BH FDR p < 0.05.
Protein co-expression network analysis. Network analysis was performed in
Banner and BLSA datasets separately to identify modules of co-expressed proteins.
For the Banner network, missing proteins were imputed using the k-nearest
neighbor imputation function in R. Then, batch effects were removed using
Combat64, and age at death, sex, and PMI were regressed from the proteomic
proﬁles using Bootstrap regression. Weighted gene co-expression network analysis
(WGCNA)68 was used on normalized protein abundance to deﬁne protein co-
expression networks. For BLSA, we used the BLSA networks from Seyfried et al.23,
which were previously built using proteins measured from the precuneus and
prefrontal cortex in the same individual. We deﬁned hub proteins, i.e., highly
connected proteins, for each of the modules as those with intramodular kME in the
top 90th percentile among the proteins in the corresponding module68. Gene
ontology (GO) enrichment analysis was performed on each protein co-expression
module using GO Elite and Fisher exact test69 to glean a deeper biological
understanding of these modules.
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Enrichment analysis of cognitive trajectory proteins. GO enrichment analysis
was performed on the proteins associated with cognitive trajectory at FDR < 0.05
from the meta-analysis. Proteins were categorized into two lists for GO enrichment
analysis: (i) higher-abundance in cognitive stability, and (ii) lower-abundance in
cognitive stability. Gene sets were downloaded from MSigDB (version 2017),
including GO biological process, cellular component, and molecular function. We
also downloaded the cell type-speciﬁc protein expression in the brain generated by
Sharma et al.19, as well as cell type-speciﬁc gene expression data generated by
Darmanis et al.21 and Zeisel et al.20 to assess for enrichment of the signiﬁcantly
associated proteins/genes in particular brain cell types. For enrichment analysis, we
used a modiﬁed version of the GeneOverlap function (from package of the same
name) in R and Fisher’s exact test so that all pair-wise tests were adjusted for
multiple testing using BH method to control the FDR67. The Fisher’s test function
also provides an estimated odds-ratio in comparison to a proteomic background set
to 20,000.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All proteomic and phenotypic data that support the ﬁndings of this study are contained
in Supplementary Data 1 and in https://www.synapse.org/#!Synapse:syn7170616 and
https://www.synapse.org/#!Synapse:syn3606086. Source data underlying Fig. 5 are
provided as a Source Data ﬁle. A reporting summary for this Article is available as
a Supplementary Information ﬁle. All other data supporting the ﬁndings of this study are
available from the corresponding authors on reasonable request.
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